CELL SIGNALING TECHNOLOGY ANNOUNCES CONTINUATION OF COLLABORATION WITH ASTRAZENECA

Cell Signaling Technology, Inc. (CST) announced today a third agreement with AstraZeneca under which it will continue to perform CST's PhosphoScan technology to identify phosphorylation profiles and prospective biomarkers of kinase targeted lead compounds. CST's PhosphoScan proteomics technology is a patent-pending strategy that enables the discovery of drug target phospho-profiles in cells and disease tissues.
Business Wire